Benign prostatic hyperplasia (BPH). Enlarged prostate with lower urinary tract symptoms
Conditions
Interventions
Intervention 1: Intervention group (first stage) : 50 milligram sildenafil tablet, nightly, for 6 weeks. Intervention 2: Intervention group( second stage) : 5 milligram tadalafil tablet, nightly, for
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Diagnosed with Benign Prostatic Hyperplasia (BPH) with lower urinary tract symptoms(LUTS) No prior history of other treatments in last month
Exclusion criteria
Exclusion criteria: Unwilling to take part in the study Concurrent treatment with Nitrates History of cardiac diseases or hypotension History of prostate surgery History of Lumbar discopathy or prior herniated disc surgery History of extensive pelvic or perineal surgeries Being a known case of neurogenic bladder or presence of its symptoms Having an active urinary tract infection (UTI)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-void residue (PVR). Timepoint: Measurement of post-void residue on first appointment( before treatment with sildenafil) and after 6 weeks (after treatment with sildenafil), 10 weeks( after washout period and before treatment with tadalafil) and 16 weeks( after treatment with tadalafil). Method of measurement: Bladder ultrasonography.;International Prostate Symptom Score (IPSS). Timepoint: Calculation of International Prostate Symptom Score(IPSS) on first appointment( before treatment with sildenafil) and after 6 weeks (after treatment with sildenafil), 10 weeks( after washout period and before treatment with tadalafil) and 16 weeks( after treatment with tadalafil). Method of measurement: IPSS questionnaire.;Initial prostate size. Timepoint: prior to treatment. Method of measurement: prostate ultrasonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMazyar Zahir
Islamic Azad University
Outcome results
None listed